Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation

Cancer Cell

Volumn 25, Issue 4, 2014, Pages 428-441

  Pilati, Camilla ^a,b   Letouzé, Eric ^c   Nault, Jean Charles ^a,b   Imbeaud, Sandrine ^a,b   Boulai, Anaïs ^a,b   Calderaro, Julien ^a,b,d   Poussin, Karine ^a,b   Franconi, Andrea ^a,b   Couchy, Gabrielle ^a,b   Morcrette, Guillaume ^a,b   Mallet, Maxime ^a,b   Taouji, Saïd ^e   Balabaud, Charles ^e   Terris, Benoit ^f   Canal, Frédéric ^g   Paradis, Valérie ^h   Scoazec, Jean Yves ⁱ   deMuret, Anne ^j   Guettier, Catherine ^k,l   Bioulac Sage, Paulette ^e,m   Chevet, Eric ^e   Calvo, Fabien ⁿ   Zucman Rossi, Jessica ^a,b,o   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Ligue Nationale Contre le Cancer   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f Cochin Hospital ^*  (France)

^g INSTITUT COCHIN   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j SERVICE DE DERMATOLOGIE   (France)

^k BICÊTRE HOSPITAL   (France)

^l HÔPITAL PAUL BROUSSE   (France)

^m HÔPITAL PELLEGRIN   (France)

ⁿ INSTITUT NATIONAL DU CANCER   (France)

^o HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLYCOPROTEIN GP 130; JANUS KINASE 1; PROTEIN KINASE; PROTEIN KINASE FRK; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; COPY NUMBER VARIATION; EXOME; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADENOMA, LIVER CELL; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MICE; MUTATION; NEOPLASM PROTEINS; NIH 3T3 CELLS; PROTEIN-TYROSINE KINASES; RISK FACTORS; TRANSFECTION;

EID: 84898445933     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.03.005     Document Type: Article

References (44)

1. Acevedo L.G., Bieda M., Green R., Farnham P.J. Analysis of the mechanisms mediating tumor-specific changes in gene expression in human liver tumors. Cancer Res. 2008, 68:2641-2651.
2. Bacq Y., Jacquemin E., Balabaud C., Jeannot E., Scotto B., Branchereau S., Laurent C., Bourlier P., Pariente D., de Muret A., et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003, 125:1470-1475.
3. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J.F., Saric J., Sa Cunha A., Rullier A., Cubel G., Couchy G., Imbeaud S., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748.
4. Bioulac-Sage P., Laumonier H., Couchy G., Le Bail B., Sa Cunha A., Rullier A., Laurent C., Blanc J.F., Cubel G., Trillaud H., et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009, 50:481-489.
5. Bluteau O., Jeannot E., Bioulac-Sage P., Marqués J.M., Blanc J.F., Bui H., Beaudoin J.C., Franco D., Balabaud C., Laurent-Puig P., Zucman-Rossi J. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 2002, 32:312-315.
6. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 1998, 18:2553-2558.
7. Cadoret A., Ovejero C., Saadi-Kheddouci S., Souil E., Fabre M., Romagnolo B., Kahn A., Perret C. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001, 61:3245-3249.
8. Calderaro J., Labrune P., Morcrette G., Rebouissou S., Franco D., Prévot S., Quaglia A., Bedossa P., Libbrecht L., Terracciano L., et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J.Hepatol. 2013, 58:350-357.
9. Chen Y.J., Chen P.J., Lee M.C., Yeh S.H., Hsu M.T., Lin C.H. Chromosomal analysis of hepatic adenoma and focal nodular hyperplasia bycomparative genomic hybridization. Genes Chromosomes Cancer 2002, 35:138-143.
10. Clark S.J., Melki J. DNA methylation and gene silencing in cancer: which is the guilty party?. Oncogene 2002, 21:5380-5387.
11. Fasan A., Kern W., Grossmann V., Haferlach C., Haferlach T., Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 2013, 27:1598-1600.
12. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., Ariola C., Fodale V., Clappier E., Paoloni F., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J.Exp. Med. 2008, 205:751-758.
13. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
14. Grivennikov S.I., Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 2010, 20:65-71.
15. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., Calderaro J., Bioulac-Sage P., Letexier M., Degos F., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44:694-698.
16. Harada N., Miyoshi H., Murai N., Oshima H., Tamai Y., Oshima M., Taketo M.M. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res. 2002, 62:1971-1977.
17. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
18. Hosoya N., Qiao Y., Hangaishi A., Wang L., Nannya Y., Sanada M., Kurokawa M., Chiba S., Hirai H., Ogawa S. Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes Chromosomes Cancer 2005, 42:269-279.
19. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
20. Jeannot E., Mellottee L., Bioulac-Sage P., Balabaud C., Scoazec J.Y., Tran Van Nhieu J., Bacq Y., Michalak S., Buob D., Laurent-Puig P., et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes 2010, 59:1836-1844. Groupe d'étude Génétique des Tumeurs Hépatiques (INSERM Network).
21. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., Friedman A.H., Friedman H., Gallia G.L., Giovanella B.C., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 2013, 110:6021-6026.
22. Koskela H.L., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmäki H., Andersson E.I., Lagström S., Clemente M.J., Olson T., Jalkanen S.E., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N.Engl. J. Med. 2012, 366:1905-1913.
23. Laumonier H., Bioulac-Sage P., Laurent C., Zucman-Rossi J., Balabaud C., Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008, 48:808-818.
24. Lee J., Kim J.C., Lee S.E., Quinley C., Kim H., Herdman S., Corr M., Raz E. Signal transducer and activator of transcription 3 (STAT3) protein suppresses adenoma-to-carcinoma transition in Apcmin/+ mice via regulation of Snail-1 (SNAI) protein stability. J.Biol. Chem. 2012, 287:18182-18189.
25. Letouzé E., Allory Y., Bollet M.A., Radvanyi F., Guyon F. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol. 2010, 11:R76.
26. Liu J., Lee W., Jiang Z., Chen Z., Jhunjhunwala S., Haverty P.M., Gnad F., Guan Y., Gilbert H.N., Stinson J., et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012, 22:2315-2327.
27. Musteanu M., Blaas L., Mair M., Schlederer M., Bilban M., Tauber S., Esterbauer H., Mueller M., Casanova E., Kenner L., et al. Stat3 is anegative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 2010, 138:1003-1011.
28. Nault J.C., Fabre M., Couchy G., Pilati C., Jeannot E., Tran Van Nhieu J., Saint-Paul M.C., De Muret A., Redon M.J., Buffet C., et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J.Hepatol. 2012, 56:184-191.
29. Nault J.C., Bioulac-Sage P., Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013, 144:888-902.
30. Nault J.C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013, 4:2218.
31. Ong C.K., Subimerb C., Pairojkul C., Wongkham S., Cutcutache I., Yu W., McPherson J.R., Allen G.E., Ng C.C., Wong B.H., et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet. 2012, 44:690-693.
32. Pilati C., Amessou M., Bihl M.P., Balabaud C., Nhieu J.T., Paradis V., Nault J.C., Izard T., Bioulac-Sage P., Couchy G., et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J.Exp. Med. 2011, 208:1359-1366.
33. Pontoglio M., Faust D.M., Doyen A., Yaniv M., Weiss M.C. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. Mol. Cell. Biol. 1997, 17:4948-4956.
34. Poussin K., Pilati C., Couchy G., Calderaro J., Bioulac-Sage P., Bacq Y., Paradis V., Leteurtre E., Sturm N., Ramos J., et al. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology 2013, 2:e27090.
35. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., Izard T., Balabaud C., Bioulac-Sage P., Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
36. Rooks J.B., Ory H.W., Ishak K.G., Strauss L.T., Greenspan J.R., Hill A.P., Tyler C.W. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. J.Am. Med. Assoc. 1979, 242:644-648.
37. Staerk J., Kallin A., Demoulin J.B., Vainchenker W., Constantinescu S.N. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J.Biol. Chem. 2005, 280:41893-41899.
38. Stefanska B., Huang J., Bhattacharyya B., Suderman M., Hallett M., Han Z.G., Szyf M. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 2011, 71:5891-5903.
39. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N.Engl. J. Med. 2006, 354:2531-2541.
40. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 1998, 18:2545-2552.
41. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N.Engl. J. Med. 1988, 319:525-532.
42. Yim E.K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.Y. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
43. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., Easton J., Chen X., Wang J., Rusch M., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
44. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S., Bacq Y., Leteurtre E., Paradis V., Michalak S., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.